M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Return to Archives
New Search
OSI says Tarceva to be reviewed by FDA committee for use as first-line maintenance therapy in advanced NSCLC
16 November 2009 - US-based OSI Pharmaceuticals Inc (NASDAQ: OSIP) said today that FDA's Oncologic Drugs Advisory Committee (ODAC) will review the use of Tarceva (erlotinib) as a first-line maintenance therapy for patients with advanced non-small cell lung cancer (NSCLC) who have not progressed...
If you want to view the full text of this story, you must first purchase archive retrieval credits.